S9 Ep11: FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Jul 17, 2023
13:39
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Agarwal discusses the significance of the FDA approval of talazoparib plus enzalutamide in HRR gene–mutated mCRPC, key efficacy and safety data from the TALAPRO-2 trial, and how this combination further supports the use of PARP inhibitors in the mCRPC treatment paradigm.
OncLive® On Air